Tech advocates headed to Annapolis for Invest Maryland hearings

Small business owners, bioscience and technology industry entrepreneurs, and business advocates are expected to jam into hearing rooms in Annapolis on Wednesday as the General Assembly’s two key budget committees hear an administration bill to create Invest Maryland — premium tax credit program aimed at generating $100 million in...

GBC seeks nominations for 2011 Bioscience Awards

The sixth annual awards, which recognize outstanding achievement in Maryland’s growing bioscience industry, will be presented on March 29 at the University of Maryland, Baltimore Bio Park. “Maryland’s bioscience industry growth is accelerating,” said GBC president and CEO Donald C. Fry. “These annual awards celebrate the innovative work of the researchers, entrepreneurs, and visionaries who are driving Maryland’s progress as a major bioscience research and industry center.” The four award … Continue reading

GBC seeks nominations for 6th Annual Maryland Bioscience Awards

The Greater Baltimore Committee is seeking nominations for the Sixth Annual Maryland Bioscience Awards to be held on March 29. The four award categories are: Outstanding Entrepreneur, Best New Product or Progress, Leadership in Bioscience, and President’s Award. Nominators will be asked to submit documentation and narratives that fulfill several criteria and then to add other supporting evidence as deemed suitable. Self-nominations are accepted and encouraged. Nominations are open January … Continue reading

Donald Fry: MedImmune CEO frames bright future for bioscience

By Donald Fry For bioscience entrepreneurs and advocates who are working to strengthen bioscience industry growth in Maryland, meeting Peter Greenleaf, the new president of Gaithersburg-based MedImmune, and listening to what he has to say is both refreshing and enlightening. In a time of global recession MedImmune, Maryland’s most prominent bioscience company, is on a hiring binge. Since 2007, when it was acquired by global pharma giant AstraZeneca to become, … Continue reading

GBC BioPark Update: Despite the recession, bioscience growth still percolates in Baltimore

The recession has clearly affected the recent pace of growth in the Baltimore region’s three major bioscience and research parks. But, after listening to an update that managers of the parks delivered to Greater Baltimore Committee members this week, it’s easy to also recognize that bioscience industry growth is still percolating in the Baltimore region. Key information reported at the GBC’s BioParks event on May 11 suggests that bioscience development … Continue reading

GBC-supported tax credits gain passage in 2010 Assembly session

In a 2010 General Assembly session punctuated by more fiscal shuffling to close yet another budget deficit, lawmakers managed to pass a number of bills, including several key tax credits, that could favorably impact the state’s business competitiveness. GBC-supported measures that passed the General Assembly included bills to continue and broaden an incentive program for historic building rehabilitation, to fund tax credits for bioscience investment, to extend tax credits for … Continue reading

GBC to celebrate bioscience achievement 5th Annual Maryland Bioscience Awards

The Greater Baltimore Committee will honor Maryland bioscience companies for outstanding achievement and entrepreneurship at the 5th Annual Maryland Bioscience Awards on March 25.  The event will be held from 8:30-10 a.m. at the Renaissance Harborplace Hotel 202 East Pratt Street Baltimore, Md. 21202. Four award categories are: Outstanding Entrepreneur, Best New Product or Progress, Leadership in Bioscience, and President’s Award. Judges for the awards are: Dr. Paul Silber, principal, Silber … Continue reading

Fyodor Biotech relocates to the University of Maryland BioPark

The new facility includes executive office and laboratory space for research and development activities, including for Fyodor’s urine-based malaria diagnostic assay. “Fyodor is now able to conduct its own research and development activities, in addition to the considerable effort currently underway at our contract development laboratory,” said Eddy Agbo, DVM, PhD, chairman and CEO of Fyodor Biotechnologies. Dr. Agbo added that “the advantages offered by the University of Maryland BioPark … Continue reading

Greater Baltimore Committee priorities for 2010 General Assembly

Preserving Maryland’s bioscience investment tax credits and other business incentives, support for charter schools and higher education resources, protecting the state’s transportation funding from being used for other purposes, and nurturing the growth of small businesses are among the Greater Baltimore Committee’s priorities for the 2010 session of the Maryland General Assembly, which convenes this week on January 13. “Recognizing that business, not government, creates jobs, our elected leaders must … Continue reading

GBC’s Fry: Maryland needs a consensus on business climate

Don Fry Commentary on WYPR: Maryland has many economic development strengths to build on – life sciences, health care, technology, and defense industries; its transportation resources, highly-educated workforce, and quality of life, to mention just a few. Most corporate leaders outside Maryland are aware of the reality of these strengths, but perceptions are everything when CEOs elsewhere consider our state as a business location or existing Maryland businesses consider expansion … Continue reading